查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1850414

重组蛋白市场按应用、产品类型、表达系统、最终用户、形式和销售管道划分－2025-2032 年全球预测

Recombinant Proteins Market by Application, Product Type, Expression System, End User, Form, Sales Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年重组蛋白市场规模将达到 175.7 亿美元，复合年增长率为 14.85%。

主要市场统计数据
基准年2024年 58亿美元
预计2025年 66.5亿美元
预测年份：2032年 175.7亿美元
复合年增长率（%） 14.85%

关于重组蛋白动力学的简明执行方向，强调对治疗、诊断和生物製造领域领导地位的策略意义。

重组蛋白是现代生命科学的基础，涵盖诊断、治疗发展、疫苗生产和基础研究。本执行摘要汇集了影响重组蛋白供应链、技术平台、最终用户采用和监管活动的最重要结构性发展。本书旨在帮助高阶主管快速了解重塑竞争定位的力量，并确定能够确保连续性和促进成长的当务之急。

以下几页将分析技术曲折点、监管压力点、商业性细分、区域企业发展考量，以及企业可以采取的实际行动，以增强韧性并获得下游价值。报告着重于定性趋势和策略影响，而非定量的市场规模，旨在帮助经营团队和跨职能领导者将洞见融入规划、投资组合优化和采购决策中。透过将科学趋势与商业性现实相结合，报告阐明了哪些投资和能力建设将带来最大的营运和策略回报。

製造敏捷性、设计自动化以及技术和商业性曲折点的结合将重新定义重组蛋白的监管预期

重组蛋白领域正在经历几场同步变革，这些变革正在重塑技术轨迹和商业性模式。首先，表达系统和下游加工製程的进步缩短了纯化时间并提高了功能性产量；而一次性生物製程、无细胞合成和模组化纯化架构等平台技术的普及，则提高了生产布局的灵活性，并降低了某些产品类别的资本密集度。

其次，数据主导的设计和自动化正在加速产品开发週期。机器学习模型正应用于序列最佳化、溶解度预测和过程参数调整，从而缩短实验週期并降低失败率。第三，监管要求正朝着更加重视製程理解和设计品质的方向发展，这促使製造商在开发早期阶段纳入即时分析和更完善的文件实践。

第四，契约製造製造商和服务供应商正在整合其能力，提供集研发支援、规模化生产和商业级供应于一体的端到端解决方案。这种垂直整合满足了客户对低风险外包关係的需求，但也增加了独立供应商的竞争压力。最后，精准医疗、诊断多样化和疫苗平台创新推动的终端用户需求的转变，正在改变产品规格和分销模式，为整个价值链的敏捷性和伙伴关係关係创造了新的战略要务。

评估2025年关税如何改变生技药品的筹资策略、区域生产决策和采购风险缓解

2025年美国关税的累积影响，为采购重组蛋白、原料和生物工程耗材的组织带来了新的成本和物流考量。关税带来的成本压力正促使买家重新考虑其供应商组合，加快在中立司法管辖区内寻找替代供应商的资格，并重新谈判长期合约以纳入关税转嫁机制。因此，采购团队正在采取更积极的对冲策略，并优先考虑多方采购，以保持供应的连续性。

同时，关税也影响供应链架构的决策，促使企业转向探索生产在地化和近岸外包机会，以减少贸易摩擦的影响。这一趋势影响生产力计画、监管备案和品质监管，因为在地化生产通常需要并行的检验活动和统一的品质系统。因此，企业正在投资统一的文件和品管平台，以使跨境生产更加可行。

此外，关税政策提高了上游投入（例如细胞层析法树脂和一次性材料）的重要性，促使客户建立策略性库存，并尽可能探索替代策略。同时，一些公司正在寻求更长期的策略选择，例如本地化原材料供应商和内包之前外包的组件。这些转变凸显了情境规划和合约弹性的必要性，以缓解贸易政策波动并维持专案进度。

将应用需求、产品化学、表达平台、使用者类型、格式和销售模式与策略性产品和服务设计连结的多维細項分析

细分洞察揭示了跨应用、产品类型、表达系统、最终用户、外形规格和销售管道的多样化价值驱动因素，这些因素影响着组织如何确定投资优先顺序和商业性方法。诊断领域分为影像诊断和体外诊断；研发领域分为基础研究、药物发现和製程开发；治疗领域包括自体免疫、循环系统和肿瘤学应用；疫苗领域分为预防性药物和治疗性药物。每个应用领域都有不同的性能规格、监管考虑和客户期望，需要量身定制的产品设计和支援服务。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 利用重组蛋白支架扩展模组化抗体药物复合体用于标靶肿瘤治疗
  • 透过整合植物瞬时表达系统加速大规模疫苗抗原生产
  • 利用新型佐剂结合重组抗原开发人工蛋白质次单元疫苗
  • 应用CRISPR/Cas9基因组编辑优化微生物宿主中重组酶的表达
  • 采用连续灌註生物反应器进行高产量单株抗体製造工艺
  • 合成生物学的进步使得重组蛋白的定製糖工程成为可能，从而提高了其功效。

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章重组蛋白市场的应用

  • 诊断
    • 造影
    • 体外诊断
  • 研究与开发
    • 基础研究
    • 药物研发
    • 製程开发
  • 治疗药物
    • 自体免疫
    • 心血管系统
    • 肿瘤学
  • 疫苗
    • 预防
    • 治疗

9. 重组蛋白市场（依产品类型）

  • 细胞激素
  • 酵素
  • 生长因子
  • 荷尔蒙

第 10 章重组蛋白市场表现系统

  • 细菌
    • 大肠桿菌
  • 昆虫
    • 桿状病毒表达
  • 哺乳动物
    • CHO细胞
    • HEK细胞
  • 植物
    • 基因改造植物
  • 酵母菌
    • 毕赤酵母
    • 酿酒酵母

第 11 章。重组蛋白市场（按最终用户划分）

  • 学术研究机构
  • 合约研究组织
  • 诊断实验室
  • 製药和生物技术公司
    • 大型製药公司
    • 中小型生技公司

第 12 章 重组蛋白市场（依形式）

  • 液体
  • 冻干形式

第 13 章重组蛋白市场（按销售管道）

  • 直销
  • 销售合作伙伴

14. 重组蛋白市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章重组蛋白市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章 各国重组蛋白市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Sartorius AG
    • Lonza Group Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Boehringer Ingelheim International GmbH
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Abcam plc
Product Code: MRR-501246437434

The Recombinant Proteins Market is projected to grow by USD 17.57 billion at a CAGR of 14.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.80 billion
Estimated Year [2025] USD 6.65 billion
Forecast Year [2032] USD 17.57 billion
CAGR (%) 14.85%

A concise executive orientation to recombinant protein dynamics highlighting strategic implications for leadership in therapeutics, diagnostics, and biomanufacturing

Recombinant proteins have become foundational to modern life sciences, spanning diagnostics, therapeutic development, vaccine production, and fundamental research. This executive summary synthesizes the most salient structural developments affecting recombinant protein supply chains, technology platforms, end-user adoption, and regulatory dynamics. It is designed to help senior leaders quickly assimilate the forces reshaping competitive positioning and to identify near-term priorities that protect continuity and enable growth.

The following pages analyze technological inflection points, regulatory pressure points, commercial segmentation, regional operating considerations, and practical actions that organizations can deploy to strengthen resiliency and capture downstream value. Emphasis is placed on qualitative trends and strategic implications rather than quantitative market sizing, enabling executive teams and cross-functional leaders to incorporate insights into planning, portfolio optimization, and sourcing decisions. By integrating scientific trends with commercial realities, this report clarifies where investment and capability-building will yield the greatest operational and strategic returns.

A synthesis of concurrent technological and commercial inflection points that are redefining manufacturing agility, design automation, and regulatory expectations for recombinant proteins

The recombinant protein landscape is undergoing multiple concurrent shifts that together reconfigure technical pathways and commercial models. First, advances in expression systems and downstream processing have reduced time-to-purity and improved functional yields, enabling more rapid iteration between discovery and preclinical validation. Alongside that, the proliferation of platform technologies such as single-use bioprocessing, cell-free synthesis, and modular purification architectures has increased flexibility in manufacturing footprints and lowered capital intensity for certain product classes.

Second, data-driven design and automation are accelerating product development cycles. Machine learning models are being applied to sequence optimization, solubility prediction, and process parameter tuning, which shortens experimental cycles and reduces failure rates. Third, regulatory expectations are evolving toward greater emphasis on process understanding and quality by design, prompting manufacturers to incorporate real-time analytics and more robust documentation practices earlier in development.

Fourth, contract manufacturing and service providers are consolidating capabilities to offer end-to-end solutions that combine R&D support, scale-up, and commercial-grade supply. This vertical integration addresses customer demand for de-risked outsourcing relationships but also raises competitive pressure on independent suppliers. Finally, changing end-user requirements-driven by precision medicine, diagnostic diversification, and vaccine platform innovation-are shifting product specifications and distribution models, creating new strategic imperatives for agility and partnerships across the value chain.

An evaluative view of how 2025 tariff measures have reshaped sourcing strategies, regional production decisions, and procurement risk mitigation for biologics stakeholders

The cumulative effects of United States tariff actions in 2025 have introduced new cost and logistical considerations for organizations sourcing recombinant proteins, raw materials, and bioprocessing consumables. Tariff-induced cost pressures have prompted buyers to reconsider supplier portfolios, accelerate qualification of alternative vendors in neutral jurisdictions, and renegotiate long-term contracts to incorporate tariff pass-through mechanisms. As a result, procurement teams are adopting more active hedging strategies and are increasingly prioritizing multi-sourcing to preserve supply continuity.

Concurrently, tariffs have influenced supply chain architecture decisions, encouraging a shift toward regionalization of production and the exploration of nearshoring opportunities to reduce exposure to trade frictions. This trend has implications for capacity planning, regulatory filings, and quality oversight, since regionalizing production often requires parallel validation activities and harmonization of quality systems. Firms are therefore investing in harmonized documentation and quality management platforms to make cross-jurisdictional manufacturing more feasible.

Additionally, tariff policies have elevated the importance of upstream inputs-such as cell culture media components, chromatography resins, and single-use materials-driving customers to secure strategic inventories and to explore substitution strategies where feasible. In parallel, some companies are pursuing longer-term strategic options, including localized raw material suppliers and incremental in-house production of previously outsourced components. These shifts emphasize the need for scenario planning and contract flexibility to mitigate trade policy volatility and maintain program timelines.

A multidimensional segmentation analysis tying application needs, product chemistry, expression platforms, user types, formats, and sales models to strategic product and service design

Segmentation insights reveal divergent value drivers across applications, product types, expression systems, end users, form factors, and sales channels that impact how organizations prioritize investments and commercial approaches. Based on application, the landscape spans Diagnostics, Research and Development, Therapeutics, and Vaccines; Diagnostics further differentiates between Imaging Agents and In Vitro Diagnostics, Research and Development breaks down into Basic Research, Drug Discovery, and Process Development, Therapeutics includes Autoimmune, Cardiovascular, and Oncology applications, while Vaccines separate into Prophylactic and Therapeutic categories. Each application area carries distinct performance specifications, regulatory considerations, and customer expectations, necessitating tailored product design and support services.

Based on product type, the portfolio includes Cytokines, Enzymes, Growth Factors, and Hormones, each representing different stability profiles, dosing contexts, and formulation challenges that affect manufacturing and distribution strategies. Based on expression system, offerings originate from Bacterial, Insect, Mammalian, Plant, and Yeast systems; the Bacterial pathway often centers on E. coli, Insect expression leverages baculovirus systems, Mammalian platforms typically use CHO or HEK cells, Plant production exploits transgenic plant approaches, and Yeast systems include Pichia pastoris and Saccharomyces cerevisiae. These expression choices dictate process complexity, post-translational modification patterns, and downstream purification requirements.

Based on end user, demand is driven by Academic and Research Institutes, Contract Research Organizations, Diagnostic Laboratories, and Pharmaceutical and Biotech Companies, with the latter further classified into Large Pharma and Small and Medium Biotech, each with differing procurement cycles, regulatory sophistication, and customization needs. Based on form, products are offered in Liquid and Lyophilized presentations that present trade-offs between cold-chain dependency and on-site preparation. Finally, based on sales channel, access to end users occurs via Direct Sales or Distribution Partners, which in turn influences service levels, lead times, and customer support models. Taken together, these segmentation dimensions create a matrix of service and product expectations that businesses must navigate to align R&D, manufacturing, and commercial strategies with customer-specific value propositions.

A comparative regional appraisal revealing how Americas, Europe Middle East & Africa, and Asia-Pacific priorities influence production location, regulatory alignment, and partnership models

Regional dynamics continue to determine operational priorities, regulatory strategies, and partnership opportunities for stakeholders across the recombinant protein value chain. In the Americas, demand drivers include a strong therapeutic development ecosystem, dense networks of contract service providers, and a regulatory environment focused on process robustness; the region favors speed to clinic and integrated supply partnerships, which shapes procurement timelines and quality expectations. The Americas also see ongoing investments in capacity expansion and in advanced analytics to support process understanding and lifecycle management.

In Europe, Middle East & Africa, regulatory harmonization and cross-border collaboration are prominent themes, with EU frameworks emphasizing rigorous process control and traceability. This region balances high technical standards with diverse national reimbursement and access considerations, prompting companies to adopt adaptable product specifications and labelling strategies. The Middle East and Africa are emerging as targeted growth corridors for clinical trial activity and for strategic manufacturing partnerships that reduce time-to-market for certain localized applications.

In Asia-Pacific, rapid expansion of biotech hubs, strong contract manufacturing capabilities, and cost-competitive production resources create attractive options for scale-up and commercial supply. Regional regulators are progressively aligning standards with international expectations while also supporting domestic innovation through incentive programs. Together, these regional distinctions influence choices around manufacturing location, regulatory submission sequencing, and partner selection, making geographic strategy a central element of commercial planning.

An examination of how capability modularity, strategic partnerships, vertical integration, and data-enabled services create competitive advantage among recombinant protein providers

Key company-level insights center on capability concentration, partnership strategies, and the interplay between proprietary platforms and service offerings. Leading organizations are investing in platform modularity that allows them to move from discovery-grade production to commercial supply with lower marginal cost and shortened timelines. This modularity extends from expression system flexibility to scalable downstream unit operations and standardized quality systems that facilitate cross-site transfers. In turn, companies that can demonstrate robust tech transfer pathways and transparent quality metrics gain preference among large developers and contract manufacturers.

Strategic partnerships are increasingly used to fill capability gaps quickly, with companies forming alliances across IP owners, contract development manufacturers, analytical specialists, and distribution networks. Licensing and co-development arrangements frequently focus on enabling technologies such as high-throughput expression screening, advanced purification chemistries, and analytics for critical quality attributes. Simultaneously, some firms are vertically integrating to capture higher-margin service layers, offering bundled solutions that span R&D reagents through to commercial supply and regulatory support.

Competitive differentiation also emerges from service excellence in regulatory support, lot-release analytics, and cold-chain logistics. Firms that invest in digital documentation, real-time release testing, and customer-facing portals strengthen long-term relationships and reduce friction during scale-up. Finally, talent and scientific leadership remain crucial; organizations that attract cross-disciplinary teams-combining molecular biology, process engineering, regulatory affairs, and data science-are better positioned to translate technological advances into commercial advantage.

Practical and strategic initiatives for executive teams to enhance manufacturing flexibility, supplier resilience, analytical rigor, and commercial differentiation in biologics

Industry leaders should pursue a balanced set of tactical and strategic initiatives to enhance resilience and capture differentiated value in recombinant protein ecosystems. First, prioritize multi-modal expression capacity and process flexibility so that product candidates can be matched to the most appropriate production route early in development; this reduces later-stage surprises and optimizes product attributes such as glycosylation and folding. Second, invest in analytics and automation to support quality by design principles, which in turn streamlines regulatory interactions and shortens validation timelines.

Third, strengthen supplier relationships through longer-term agreements with contractual clauses that address trade disruptions, inventory buffers, and cooperative contingency planning. Firms should also qualify secondary and tertiary suppliers proactively to ensure rapid substitution when needed. Fourth, adopt a regional production strategy that balances cost, regulatory alignment, and speed to market; nearshoring certain critical steps while centralizing high-complexity operations can yield improved control without forfeiting efficiency.

Fifth, develop differentiated commercial offerings by bundling technical support, regulatory guidance, and data transparency with product sales, thereby converting reagent transactions into strategic partnerships. Sixth, implement talent development programs that bridge biology and data science to ensure organizations can leverage machine learning and process analytics effectively. Finally, execute scenario-based stress tests that incorporate tariff volatility, supply interruptions, and demand surges to refine playbooks for procurement, production scaling, and customer communication.

An overview of the evidence-based methodological approach combining expert interviews, authoritative technical sources, and scenario analysis to derive actionable qualitative insights

This research synthesized primary and secondary sources to develop an evidence-based, qualitative perspective on recombinant protein dynamics, emphasizing methodological transparency and reproducibility. Primary research included structured interviews with subject-matter experts across bioprocess engineering, regulatory affairs, procurement, and commercial strategy, supplemented by technical briefings from analytics providers and contract manufacturers. These interviews were designed to surface operational constraints, validation challenges, and buyer expectations rather than to elicit proprietary financials.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures that relate to expression technologies, purification methods, and regulatory frameworks. Where regulatory interpretations were discussed, the methodology prioritized authoritative agency texts and published guidance to ensure accuracy. Data synthesis followed an iterative triangulation approach, where insights from interviews were cross-validated against documented technical approaches and publicly available process descriptions.

The analytical framework applied scenario analysis to assess the implications of supply chain disruptions, tariff changes, and technological adoption pathways. Segmentation analysis was used to map product and customer needs across application, expression system, form, and sales channel dimensions. Finally, findings were stress-tested through peer review by independent experts to confirm practical relevance and to refine recommendations for operationalization within R&D, manufacturing, and commercial teams.

A concise synthesis underscoring the strategic imperative of aligning technological choices, operational resilience, and customer-centric services to lead in recombinant protein applications

The recombinant protein sector is at an inflection point where technological maturity, regulatory emphasis on process understanding, and commercial demands for flexibility intersect. Organizations that proactively align expression system choices with downstream capabilities, invest in analytics and automation, and develop nimble sourcing strategies will be better positioned to manage risk and to accelerate translational timelines. Moreover, those that convert product transactions into value-added partnerships through bundled services and transparent performance metrics will strengthen customer retention and command better commercial outcomes.

Looking ahead, success will favor entities that integrate scientific innovation with pragmatic operational planning-balancing cost, quality, and speed while maintaining regulatory compliance. By prioritizing capability modularity, regional supply diversity, and cross-disciplinary talent, companies can create durable competitive moats. Ultimately, the ability to translate technical improvements into reliable, documented, and scalable processes will determine which organizations lead in therapeutic, diagnostic, and vaccine applications built on recombinant protein technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of modular antibody-drug conjugates using recombinant protein scaffolds for targeted oncology therapies
  • 5.2. Integration of plant-based transient expression systems to accelerate large-scale vaccine antigen production
  • 5.3. Development of engineered protein subunit vaccines using novel adjuvant-binding recombinant antigens
  • 5.4. Application of CRISPR/Cas9 genome editing for optimized recombinant enzyme expression in microbial hosts
  • 5.5. Adoption of continuous perfusion bioreactors for high-yield monoclonal antibody manufacturing processes
  • 5.6. Advances in synthetic biology enabling customizable recombinant protein glycoengineering for improved efficacy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Recombinant Proteins Market, by Application

  • 8.1. Diagnostics
    • 8.1.1. Imaging Agents
    • 8.1.2. In Vitro Diagnostics
  • 8.2. Research And Development
    • 8.2.1. Basic Research
    • 8.2.2. Drug Discovery
    • 8.2.3. Process Development
  • 8.3. Therapeutics
    • 8.3.1. Autoimmune
    • 8.3.2. Cardiovascular
    • 8.3.3. Oncology
  • 8.4. Vaccines
    • 8.4.1. Prophylactic
    • 8.4.2. Therapeutic

9. Recombinant Proteins Market, by Product Type

  • 9.1. Cytokines
  • 9.2. Enzymes
  • 9.3. Growth Factors
  • 9.4. Hormones

10. Recombinant Proteins Market, by Expression System

  • 10.1. Bacterial
    • 10.1.1. E Coli
  • 10.2. Insect
    • 10.2.1. Baculovirus Expression
  • 10.3. Mammalian
    • 10.3.1. CHO Cells
    • 10.3.2. HEK Cells
  • 10.4. Plant
    • 10.4.1. Transgenic Plants
  • 10.5. Yeast
    • 10.5.1. Pichia Pastoris
    • 10.5.2. Saccharomyces Cerevisiae

11. Recombinant Proteins Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotech Companies
    • 11.4.1. Large Pharma
    • 11.4.2. Small And Medium Biotech

12. Recombinant Proteins Market, by Form

  • 12.1. Liquid Form
  • 12.2. Lyophilized Form

13. Recombinant Proteins Market, by Sales Channel

  • 13.1. Direct Sales
  • 13.2. Distribution Partners

14. Recombinant Proteins Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Recombinant Proteins Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Recombinant Proteins Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Merck KGaA
    • 17.3.3. Danaher Corporation
    • 17.3.4. Sartorius AG
    • 17.3.5. Lonza Group Ltd.
    • 17.3.6. F. Hoffmann-La Roche Ltd.
    • 17.3.7. Boehringer Ingelheim International GmbH
    • 17.3.8. Bio-Rad Laboratories, Inc.
    • 17.3.9. Bio-Techne Corporation
    • 17.3.10. Abcam plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BACULOVIRUS EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY HEK CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY TRANSGENIC PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PICHIA PASTORIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SMALL AND MEDIUM BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY LYOPHILIZED FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DISTRIBUTION PARTNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY INSECT, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PLANT, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY YEAST, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA RECOMBINANT PROTEINS MARKET SIZE, BY RESEARCH